In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

eHealth and Cardiology

What is eHealth and why is it relevant to cardiology today? Watch videos and case studies and read the latest science on this hot topic

Read more

EU funded projects and the ESC

The ESC is involved in a number of EU funded research projects, often as a dissemination partner. Our role is fundamental to ensuring the very latest scientific best practice is shared with as many cardiovascular practitioners, researchers and institutions as possible.


ESC is a partner in this project that aims to improve care of patients with Atrial Fibrillation. Our role is to disseminate scientific findings through guideline recommendations and education programmes.

Learn more


Beta 3 is a Horizon2020 funded project with an objective to prevent patients having a structural heart remodelling and therefore at risk, to develop a heart failure. Twelve partners in eight European countries participate to the Beta3_LVH project. 

The project is a clinical trial with an already marketed drug, known to be effective in bladder disorders that will be administered to patients in a new indication.

The patients suffering from a structural and functional defect of the left ventricle are targeted. Their cardiac hypertrophy and left ventricle function will be monitored through the whole study to assess the possible benefit of the tested medication. 

The targeted population is constituted of patients carrying structural cardiac disease with or without symptoms of heart failure (up to NYHA II), i.e. at risk of developing heart failure with preserved ejection fraction (HFpEF).

BETA 3_LVH website


Aims to outline the current Cardiovascular Diseases (CVD) research and innovation landscape across Europe

Learn more about Cardioscape

Procedure for ESC involvement in EU Funded project

Nature of involvement

ESC will not participate in projects for endorsement purposes only.

Strategic & Scientific value assessment of the project

Only projects related to the ESC mission statement and ESC strategic orientations will be considered. This includes of course Working groups, Councils and Associations.

Submission procedure

  • Initial review by ESC Advocacy Chair, if acceptable then
  • Submission for assessment to ESC leadersh

ESC decision

The final decision will be taken by ESC leadership.


  • Project proposal synopsis = 8 weeks before call’s deadline
  • Complete project proposal = 6 weeks before call’s deadline

Compulsory information

  1. Synopsis
    - Indication of relevant call for proposal + submission deadline
    - Summary of project objectives
    - Relevance to ESC/constituent body mission

  2. Complete (draft) proposal
    - Project objectives
    - expected role for ESC/constituent body
    - Resources: (human & budget) implications
    - Project duration
    - Indicative project consortium